Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Activin Receptor Type 1 (Activin Receptor Like Kise 2 or Serine/Threonine Protein Kise Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Overview
Activin Receptor Type 1 (Activin Receptor Like Kise 2 or Serine/Threonine Protein Kise Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Activin Receptor Type 1 (Activin Receptor Like Kise 2 or Serine/Threonine Protein Kise Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Activin Receptor Type 1 (Activin Receptor Like Kise 2 or Serine/Threonine Protein Kise Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Companies Involved in Therapeutics Development
BioCryst Pharmaceuticals Inc
Clementia Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Incyte Corp
Keros Therapeutics Inc
La Jolla Pharmaceutical Company
M4K Pharma Inc
Oncodesign SA
Sierra Oncology Inc
Tolero Pharmaceuticals Inc
Activin Receptor Type 1 (Activin Receptor Like Kise 2 or Serine/Threonine Protein Kise Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Drug Profiles
BCX-9250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BCX-9499 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLU-782 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dipyridamole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-6016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INCB-00928 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KER-047 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
momelotinib dihydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 1 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 2 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Activin Receptor-Like Kise 2 for fibrodysplasia ossificans progressiva - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ACVR1 for Pediatric Diffuse Intrinsic Pontine Glioma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TP-0184 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Activin Receptor Type 1 (Activin Receptor Like Kise 2 or Serine/Threonine Protein Kise Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Dormant Products
Activin Receptor Type 1 (Activin Receptor Like Kise 2 or Serine/Threonine Protein Kise Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Discontinued Products
Activin Receptor Type 1 (Activin Receptor Like Kise 2 or Serine/Threonine Protein Kise Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Product Development Milestones
Featured News & Press Releases
Dec 07, 2019: Sierra Oncology reports decreased transfusion requirements for patients treated with Momelotinib directly compared to Ruxolitinib at ASH annual meeting
Dec 02, 2019: Sierra Oncology announces investor event to discuss Momelotinib data being reported at ASH
Nov 21, 2019: Sierra Oncology initiates study of momelotinib in myelofibrosis
Nov 06, 2019: Sierra Oncology to report new alyses supporting Momelotinib’s anemia benefits at ASH 2019
Nov 04, 2019: BioCryst launches trial to treat fibrodysplasia ossificans progressiva
Oct 24, 2019: Oncodesign: publication of an article presenting promising results for the treatment of stone man syndrome (FOP)
Jun 27, 2019: Sierra Oncology launches campaign exploring non-dilutive strategic options to support development of its DDR Assets
Jun 07, 2019: FDA grants fast-track desigtion to bone marrow cancer drug
Jun 04, 2019: Sierra announces FDA regulatory clarity for Momelotinib & design of the MOMENTUM phase 3 clinical trial
May 28, 2019: Sierra Oncology to Present Momelotinib Overview at the Jefferies Global Healthcare Conference in New York
Mar 27, 2019: Blueprint Medicines provides update on clinical progress of BLU-782
Feb 27, 2019: Tolero Pharmaceuticals to present new data evaluating investigatiol agent TP-0184 at AACR Annual Meeting 2019
Dec 03, 2018: Sierra Oncology reports robust transfusion independence rates in transfusion dependent myelofibrosis patients treated with momelotinib
Nov 27, 2018: Sierra Oncology to host alyst call highlighting clinical data on Momelotinib’s anemia benefit
Nov 01, 2018: Sierra Oncology to report clinical data at ASH 2018 from translatiol biology study of Momelotinib in transfusion dependent patients
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020


List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by BioCryst Pharmaceuticals Inc, H1 2020
Pipeline by Clementia Pharmaceuticals Inc, H1 2020
Pipeline by Daiichi Sankyo Co Ltd, H1 2020
Pipeline by Incyte Corp, H1 2020
Pipeline by Keros Therapeutics Inc, H1 2020
Pipeline by La Jolla Pharmaceutical Company, H1 2020
Pipeline by M4K Pharma Inc, H1 2020
Pipeline by Oncodesign SA, H1 2020
Pipeline by Sierra Oncology Inc, H1 2020
Pipeline by Tolero Pharmaceuticals Inc, H1 2020
Dormant Projects, H1 2020
Discontinued Products, H1 2020